课题基金 / 基金详情

Diet driven evolution of epidemic ribotypes of Clostridium difficile

Diet driven evolution of epidemic ribotypes of Clostridium difficile
饮食驱动艰难梭菌流行性核糖型的进化
批准号:
10053311
负责人:
ROBERT A BRITTON
金额:
$39.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-11-17 至 2022-10-31

项目摘要

项目成果

ROBERT A BRITTON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The emergence of pathogens that cause increased morbidity and mortality is a major public health concern. Clostridium difficile is a major cause of hospital acquired infection and is the leading cause of antibiotic-associated diarrhea. In the past decade, two epidemic ribotypes (RT027 and RT078) of C. difficile have emerged as major ribotypes in hospital outbreaks around the world despite not being observed at significant levels prior to the year 2000. These ribotypes are associated with increased morbidity and mortality and have been classified as hypervirulent. However, the mechanistic basis for why these strains began to emerge in the early 2000s is unclear. We have found that RT027 and RT078 strains have acquired the ability to grow on the disaccharide trehalose more efficiently than other ribotypes of C. difficile. Our preliminary data shows that the mechanistic bases for the improved growth in these two ribotypes are genetically and mechanistically distinct, suggesting convergent evolution of improved trehalose metabolism in these phylogenetically distinct ribotypes. In addition, we have found that disrupting the ability of a RT027 strain to utilize trehalose dramatically attenuates disease severity, suggesting that trehalose metabolism contributes to the hypervirulent nature of RT027 and RT078 strains. Trehalose, a disaccharide of glucose, became a widely used food supplement after being granted GRAS status approval by the FDA in 2000 and EFSA in Europe in 2001. Trehalose has a number of desirable properties as a sugar additive due to the alpha, alpha 1-1 linkage that is heat and acid stable, which renders it 45% less sweet than sucrose. Normally found in foods such as mushrooms and shellfish, trehalose is now added to numerous food and drink products ranging from ground beef to ice cream. The addition of trehalose to the worldwide food supply coincides with the first reports of RT027 and RT078 strains in the early 2000s, even though these ribotypes were present in hospitals as far back as 1985. We propose that addition of increased levels of trehalose to the food supply has selected for RT027 and RT078 strains due to their ability to more efficiently metabolize trehalose and has contributed to hospital epidemics. We will use two recently developed models in our laboratory, human fecal minibioreactor array model of C. difficile invasion and a humanized microbiota mouse model of C. difficile infection, to study the impact of trehalose and improved trehalose metabolism on the ability of RT027 and RT078 strains to cause C. difficile infection. We will also investigate the mechanistic bases for improved trehalose metabolism of RT027 and RT078 strains. Finally, we will assess what impact improved trehalose metabolism has on colonization dynamics, disease severity and carriage in animals of these hypervirulent C. difficile ribotypes. The following specific aims are proposed: Aim 1. Investigate the mechanism of how trehalose metabolism by C. difficile increases disease severity. Aim 2. Understand the mechanistic basis for improved trehalose metabolism in RT027 C. difficile. Aim 3. Understand the role of the acquired trehalose operon on RT078 fitness and animal carriage. We expect this work will establish a link between the recent addition of trehalose in the human diet and the emergence of epidemic C. difficile ribotypes. This will provide the first direct evidence of the alteration of the human diet directly impacting the pathogenesis of an enteric infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multi-method investigation and characterization of the ocular microbiome
  • 批准号:
    10660691
  • 项目类别:
  • 资助金额:
    $66.33万
  • 财政年份:
    2023
  • 负责人:
    ROBERT A BRITTON
  • 依托单位:
Engineered probiotic for the treatment of autoimmune diseases
  • 批准号:
    10561101
  • 项目类别:
  • 资助金额:
    $68.23万
  • 财政年份:
    2023
  • 负责人:
    ROBERT A BRITTON
  • 依托单位:
Defined microbial communities to prevent and eradicate infection by AMR pathogens
  • 批准号:
    10357969
  • 项目类别:
  • 资助金额:
    $40.04万
  • 财政年份:
    2021
  • 负责人:
    ROBERT A BRITTON
  • 依托单位:
Admin Core - Britton
  • 批准号:
    10583458
  • 项目类别:
  • 资助金额:
    $24.02万
  • 财政年份:
    2021
  • 负责人:
    ROBERT A BRITTON
  • 依托单位:
海外基金